Supermax Corporation Berhad Valuation

Q: What is the Fair Price of SPMX.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

SPMX.F ($0.18) is trading above our estimate of [[fair value]] ($0.11)

Is SPMX.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SPMX.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SPMX.F ($0.18) is trading above our estimate of fair value ($0.11)

Significantly Below Fair Value: SPMX.F is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SPMX.F?

Key metric: As SPMX.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SPMX.F. This is calculated by dividing SPMX.F's market cap by their current revenue.
What is SPMX.F's PS Ratio?
PS Ratio	2.4x
Sales	RM 898.72m
Market Cap	RM 2.11b

SPMX.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does SPMX.F's PS Ratio compare to its peers?

The above table shows the PS ratio for SPMX.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.3x
AVNS Avanos Medical	1.2x	4.6%	US$836.0m
EMBC Embecta	1x	1.4%	US$831.5m
CERS Cerus	1.9x	10.7%	US$338.0m
OSUR OraSure Technologies	1.3x	-15.8%	US$293.2m
SPMX.F Supermax Corporation Berhad	2.4x	30.8%	US$2.1b

Price-To-Sales vs Peers: SPMX.F is good value based on its Price-To-Sales Ratio (2.4x) compared to the peer average (6.7x).

Price to Sales Ratio vs Industry

How does SPMX.F's PS Ratio compare vs other companies in the US Medical Equipment Industry?

50 Companies	Price / Sales	Estimated Growth	Market Cap
INGN Inogen	0.7x	4.2%	US$232.94m
ARAY Accuray	0.4x	5.5%	US$204.15m
NVRO Nevro	0.4x	2.5%	US$170.50m
KEQU Kewaunee Scientific	0.6x	n/a	US$122.17m

50 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: SPMX.F is good value based on its Price-To-Sales Ratio (2.4x) compared to the US Medical Equipment industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is SPMX.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SPMX.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SPMX.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Lantheus Holdings

US$6.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$89.53

12.7%

29.8%

Elevance Health

US$94.5b

Operates as a health benefits company in the United States.

ELV

US$401.96

2.0%

-15.5%

Centene

US$31.0b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.00

3.8%

-17.8%